Home

PAUL R. FONTEYNE

CIK 1727550 · last filed 2026-08-03

PAUL R. FONTEYNE is a corporate insider who has filed 27 SEC Form 4 insider transactions across 7 companies since 2019. The most recent filing, for APMD, was dated Aug 3, 2026. Across all open-market trades the lifetime net is +$350.2K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $133.4K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$133.4K

Companies

7

Total Filings

27

Lifetime Open-Market Net

$350.2K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
APMD Director — — — $0 1 2026-08-03
AMLX Director 3,947 $33.81 $133.4K $75.0K 6 2026-06-08
Apellis Pharmaceuticals, Inc. (APLS) Delisted Director 0 $41.03 $0 $159.0K 9 2026-05-14
COVETRUS, INC. (CVET) Delisted Director 0 $20.99 $0 $116.2K 5 2022-10-13
GELESIS HOLDINGS, INC. (GLS.WS) Delisted Director 53,832 $0.01 $447 $0 1 2022-05-09
AMAG PHARMACEUTICALS, INC. (AMAG) Delisted Director 0 — — $0 3 2020-11-17
Adicet Bio, Inc. (TORC) Delisted Director — — — $0 2 2020-06-05

Recent Filings

27 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-03 APMD Mixed — $0 EDGAR
2026-06-08 AMLX Grant (A) — $0 EDGAR
2026-05-14 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed −54,854 $0 EDGAR
2026-01-05 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) +7,961 $0 EDGAR
2025-06-09 AMLX Grant (A) — $0 EDGAR
2025-01-03 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) +6,267 $0 EDGAR
2024-06-07 AMLX Grant (A) — $0 EDGAR
2024-01-02 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) +3,341 $0 EDGAR
2023-06-12 AMLX Grant (A) — $0 EDGAR
2023-01-04 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) +3,867 $0 EDGAR
Showing 1–10 of 27
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.